Evidence brief · printable

Chronic Obstructive Pulmonary Disease evidence brief

One page, every section sourced. Print it or bring it on your phone.

  1. Research Tracker
  2. Evidence briefs
  3. Chronic Obstructive Pulmonary Disease

Print or save as PDF Fits on one A4 or Letter page.

Chronic Obstructive Pulmonary Disease: evidence brief

Open Source Medicine Foundation · page built 16 November 2026 · trial data searched 2026-11-16 (capped at 1,000 of 2,688 matching trials) · https://research.opensourcemed.info/briefs/chronic-obstructive-pulmonary-disease.html

Research information, not medical advice. Prepared to support a conversation with a clinician, not to choose a treatment.

Live version

Medicines with registered trials

Scale: trials listed for each medicine on the tracker's condition page, a snapshot of ClinicalTrials.gov. A trial means it is being studied, not that it works.

  • RV568 (see NCT01475292) 2 trials
  • 18 mcg of Spiriva (Reference Product) 1 trial
  • Aclidinium bromide 1 trial
  • Adjustable bed backrest 1 trial
  • Atrovent Respimat (20 mcg) 1 trial
  • AZD 2115, Dose 2 1 trial

Non-drug approaches tested

Scale: trial status on ClinicalTrials.gov (completed, results posted). Status is not a result.

  • Education, coaching and self-management 31 trials · 14 completed · 6 with results
  • Pulmonary rehabilitation 43 trials · 17 completed · 3 with results
  • Multidisciplinary and other rehabilitation 10 trials · 3 completed · 2 with results
  • Sleep and circadian interventions 3 trials · 2 completed · 2 with results
  • Breathing and respiratory muscle training 48 trials · 26 completed · 1 with results
  • Aerobic and endurance exercise 24 trials · 8 completed · 1 with results

Natural products (RepurpOS Moderate tier)

Scale: RepurpOS evidence tier, from linked trials and literature. Product quality and dose vary.

  • Rhodiola
  • Vitamin D3
  • N-Acetylcysteine
  • Vitamin C
  • Creatine
  • L-Carnitine

Biomarkers reported

Direction in patients compared with the stated comparison group, as reported in the cited study.

  • Alpha-1 Antitrypsin lower · Dasi et al. 2024
  • CRP higher · Yanbaeva et al. 2007
  • FEV1/FVC ratio lower · Liu et al. 2025
  • FEV1 lower · Liu et al. 2025
  • Fibrinogen higher · Yanbaeva et al. 2007

Trials recruiting

Status as recorded on ClinicalTrials.gov when searched (2026-11-16); check the registry for current status and eligibility.

  • PRA-216 COPD Safety and Biomarker Study NCT07730281
  • Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination… NCT07896252
  • To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With… NCT07684820
  • Effects of COPD Standardized Management on COPD Exacerbation NCT04664491
  • Adherence to Inhaled Therapy - a Globally Overlooked Problem in Patients With… NCT07183657
  • Digital Therapy in Self-management of COPD Patients NCT06776601

What we don't know yet

Gaps in registered trials, from the evidence-gap map. A gap is not a recommendation.

  • Oxygen, light, temperature and manual therapies: breathing and lung function 10 trials, no results posted yet
  • Cognitive training and education: feasibility, adherence and safety 9 trials, no results posted yet
Sources: ClinicalTrials.gov (trials, status, posted results); RepurpOS natural-product tiers (registry trials, PubMed, reference databases); OSMF biomarker atlas where available; OSMF non-drug evidence map (309 non-drug trials for this condition). Lists are shortened; the live pages carry every entry with its source: evidence-gap map · RepurpOS · condition page · biomarker atlas. Counts change daily. Nothing here is a recommendation to start, stop or change any treatment.